Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Exit

Neighborly leaves the municipal precinct
Stanford-backed micro public finance platform Neighborly has paused the payroll in a concerted attempt to restructure the business and avert insolvency.
Biontech binds itself to public markets
Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.
Aprea closes $97.8m IPO
The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.
Apple screens iKinema for acquisition
Founded from University of Surrey's Space Centre, iKinema was bought by Apple in a move seemingly aligned with the corporate's foray into virtual and augmented reality.
Aprea collects $85m in IPO proceeds
Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
Frequency attracts $84m in IPO
Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.
Infineon lands Dice
Infineon Technologies Austria has bought its portfolio company Dice, a Johannes Kepler University spinout that produces integrated circuits for radar-powered sensors.
StretchSense reaches out for new ownership
Wearable sensor maker StretchSense, a University of Auckland spinout, has been purchased out of administration by an unnamed buyer.

Other News

Beam Therapeutics threads its way toward public markets
Harvard's genomic editing technology spinout has filed to raise up to $100m, adding to some $225m of venture funding in under three years.
Phytelligence wilts away
Phytelligence has lost its legal case with Washington State University, leaving the board with no option but to close its crop cultivation business.
Aprea apprises markets ahead of $92m IPO
Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.
Woodford unloads IP Group stake
Woodford’s stake in IP Group is being sold at a 13% discount on market trading as its suspended Equity Income fund sharply pivots to FTSE 100 investments.
Allied Minds hits the end zone at HawkEye 360
Allied Minds will collect $65.6m for its 58% stake in data analytics satellite operator HawkEye 360, which it founded on the back of Virginia Tech research.
Frequency seeks $107m in IPO
Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg

Login